Breaking Genetic Shackles: The Advance of Base Editing in Genetic Disorder Treatment

Overview

Journal Front Pharmacol

Date 2024 Mar 21

PMID 38510648

Authors

Fang Xu

Caiyan Zheng

Weihui Xu

Shiyao Zhang

Shanshan Liu

Xiaopeng Chen

Kai Yao

Affiliations

Soon will be listed here.

Abstract

The rapid evolution of gene editing technology has markedly improved the outlook for treating genetic diseases. Base editing, recognized as an exceptionally precise genetic modification tool, is emerging as a focus in the realm of genetic disease therapy. We provide a comprehensive overview of the fundamental principles and delivery methods of cytosine base editors (CBE), adenine base editors (ABE), and RNA base editors, with a particular focus on their applications and recent research advances in the treatment of genetic diseases. We have also explored the potential challenges faced by base editing technology in treatment, including aspects such as targeting specificity, safety, and efficacy, and have enumerated a series of possible solutions to propel the clinical translation of base editing technology. In conclusion, this article not only underscores the present state of base editing technology but also envisions its tremendous potential in the future, providing a novel perspective on the treatment of genetic diseases. It underscores the vast potential of base editing technology in the realm of genetic medicine, providing support for the progression of gene medicine and the development of innovative approaches to genetic disease therapy.

Citing Articles

Efficient solid-phase extraction of oligo-DNA from complex media using a nitrocellulose membrane modified with carbon nanotubes and aminated reduced graphene oxide.

Toader G, Mihalache D, Grigorean V, Chiticaru E, Pandele M, Ionita M Sci Rep. 2025; 15(1):5325.

PMID: 39948136 PMC: 11825714. DOI: 10.1038/s41598-025-89705-7.

From bench to bedside: cutting-edge applications of base editing and prime editing in precision medicine.

Xu W, Zhang S, Qin H, Yao K J Transl Med. 2024; 22(1):1133.

PMID: 39707395 PMC: 11662623. DOI: 10.1186/s12967-024-05957-3.

Anesthetic effects on electrophysiological responses across the visual pathway.

Zhang S, Xu W, Liu S, Xu F, Chen X, Qin H Sci Rep. 2024; 14(1):27825.

PMID: 39537872 PMC: 11561267. DOI: 10.1038/s41598-024-79240-2.

Perspectives on CRISPR Genome Editing to Prevent Prion Diseases in High-Risk Individuals.

Medd M, Cao Q Biomedicines. 2024; 12(8).

PMID: 39200190 PMC: 11352000. DOI: 10.3390/biomedicines12081725.

The Applications of Artificial Intelligence (AI)-Driven Tools in Virus-Like Particles (VLPs) Research.

Laxmi B, Devi P, Thanjavur N, Buddolla V Curr Microbiol. 2024; 81(8):234.

PMID: 38904765 DOI: 10.1007/s00284-024-03750-5.

References

Li Z, Li C . CRISPR/Cas9 from bench to bedside: what clinicians need to know before application?. Mil Med Res. 2020; 7(1):61. PMC: 7722470. DOI: 10.1186/s40779-020-00292-2. View

Li G, Jin M, Li Z, Xiao Q, Lin J, Yang D . Mini-dCas13X-mediated RNA editing restores dystrophin expression in a humanized mouse model of Duchenne muscular dystrophy. J Clin Invest. 2022; 133(3). PMC: 9888377. DOI: 10.1172/JCI162809. View

Zeng J, Wu Y, Ren C, Bonanno J, Shen A, Shea D . Therapeutic base editing of human hematopoietic stem cells. Nat Med. 2020; 26(4):535-541. PMC: 7869435. DOI: 10.1038/s41591-020-0790-y. View

Ogu U, Thomas M, Chan F, Vattappally L, Sebastian G, Crouch A . L-glutamine use in adults with sickle cell disease: Clinical trials where success meets reality. Am J Hematol. 2020; 96(1):E38-E40. DOI: 10.1002/ajh.26021. View

Terns M, Terns R . CRISPR-based adaptive immune systems. Curr Opin Microbiol. 2011; 14(3):321-7. PMC: 3119747. DOI: 10.1016/j.mib.2011.03.005. View

Kannan S, Altae-Tran H, Jin X, Madigan V, Oshiro R, Makarova K . Compact RNA editors with small Cas13 proteins. Nat Biotechnol. 2021; 40(2):194-197. PMC: 8929162. DOI: 10.1038/s41587-021-01030-2. View

Danciger M, Blaney J, Gao Y, Zhao D, Heckenlively J, Jacobson S . Mutations in the PDE6B gene in autosomal recessive retinitis pigmentosa. Genomics. 1995; 30(1):1-7. DOI: 10.1006/geno.1995.0001. View

Nishikura K . Functions and regulation of RNA editing by ADAR deaminases. Annu Rev Biochem. 2010; 79:321-49. PMC: 2953425. DOI: 10.1146/annurev-biochem-060208-105251. View

El Refaey M, Xu L, Gao Y, Canan B, Adesanya T, Warner S . In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice. Circ Res. 2017; 121(8):923-929. PMC: 5623072. DOI: 10.1161/CIRCRESAHA.117.310996. View

10.

Russell S, Drack A, Cideciyan A, Jacobson S, Leroy B, Van Cauwenbergh C . Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b/2 trial. Nat Med. 2022; 28(5):1014-1021. PMC: 9117145. DOI: 10.1038/s41591-022-01755-w. View

11.

Shedlovsky A, McDonald J, Symula D, Dove W . Mouse models of human phenylketonuria. Genetics. 1993; 134(4):1205-10. PMC: 1205587. DOI: 10.1093/genetics/134.4.1205. View

12.

Chen S, Liu Z, Xie W, Yu H, Lai L, Li Z . Compact Cje3Cas9 for Efficient Genome Editing and Adenine Base Editing. CRISPR J. 2022; 5(3):472-486. DOI: 10.1089/crispr.2021.0143. View

13.

Sahel J, Marazova K, Audo I . Clinical characteristics and current therapies for inherited retinal degenerations. Cold Spring Harb Perspect Med. 2014; 5(2):a017111. PMC: 4315917. DOI: 10.1101/cshperspect.a017111. View

14.

Huijgen R, Abbink E, Bruckert E, Stalenhoef A, Imholz B, Durrington P . Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther. 2010; 32(4):615-25. DOI: 10.1016/j.clinthera.2010.04.014. View

15.

Ni H, Hatit M, Zhao K, Loughrey D, Lokugamage M, Peck H . Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo. Nat Commun. 2022; 13(1):4766. PMC: 9376583. DOI: 10.1038/s41467-022-32281-5. View

16.

Singh R, Binette F, Seiler M, Petersen-Jones S, Nasonkin I . Pluripotent Stem Cell-Based Organoid Technologies for Developing Next-Generation Vision Restoration Therapies of Blindness. J Ocul Pharmacol Ther. 2020; 37(3):147-156. PMC: 8060716. DOI: 10.1089/jop.2020.0016. View

17.

Kweon J, Jang A, Kwon E, Kim U, Shin H, See J . Targeted dual base editing with Campylobacter jejuni Cas9 by single AAV-mediated delivery. Exp Mol Med. 2023; 55(2):377-384. PMC: 9981745. DOI: 10.1038/s12276-023-00938-w. View

18.

Webber B, Lonetree C, Kluesner M, Johnson M, Pomeroy E, Diers M . Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nat Commun. 2019; 10(1):5222. PMC: 6864045. DOI: 10.1038/s41467-019-13007-6. View

19.

Corey D, Akyuz N, Holt J . Function and Dysfunction of TMC Channels in Inner Ear Hair Cells. Cold Spring Harb Perspect Med. 2018; 9(10). PMC: 6450785. DOI: 10.1101/cshperspect.a033506. View

20.

Bauer D, Orkin S . Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin. Curr Opin Genet Dev. 2015; 33:62-70. PMC: 4705561. DOI: 10.1016/j.gde.2015.08.001. View